# Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

> **NCT00002234** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 25 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Efavirenz
- **DRUG:** Adefovir dipivoxil
- **DRUG:** Lamivudine
- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00002234
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 25 (—)
- **Last updated:** 2005-06-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002234, "Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*